http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 24 Oct 2024 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Cellino+Appoints+Chris+Gibson+to+Board+of+Directors/23873795.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cellinobio.com%2F&amp;esheet=54140879&amp;newsitemid=20241024933617&amp;lan=en-US&amp;anchor=Cellino+Biotech%2C+Inc.&amp;index=1&amp;md5=5a3613ab5acb4d8797c2f6fe3b89f9d1" shape="rect">Cellino Biotech, Inc.</a>, a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company’s Board of Directors. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241024933617/en/" rel="nofollow">https://www.businesswire.com/news/home/20241024933617/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241024933617/en/2282297/4/Chris_Gibson.jpg" alt="Chris Gibson, Ph.D., Co-Founder &amp; CEO, Recursion. (Photo credit: Recursion)" /><p style="font-size:85%;">Chris Gibson, Ph.D., Co-Founder &amp; CEO, Recursion. (Photo credit: Recursion)</p></div><p> Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven http://www.streetinsider.com/Press+Releases/Cellino+Appoints+Chris+Gibson+to+Board+of+Directors/23873795.html Thu, 24 Oct 2024 08:00:00 -0400 A.40151759 EXAI O.00050368 O.50752363 RXDX http://www.streetinsider.com/Press+Releases/Cellino+Appoints+Chris+Gibson+to+Board+of+Directors/23873795.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cellinobio.com%2F&amp;esheet=54140879&amp;newsitemid=20241024933617&amp;lan=en-US&amp;anchor=Cellino+Biotech%2C+Inc.&amp;index=1&amp;md5=5a3613ab5acb4d8797c2f6fe3b89f9d1" shape="rect">Cellino Biotech, Inc.</a>, a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company’s Board of Directors. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241024933617/en/" rel="nofollow">https://www.businesswire.com/news/home/20241024933617/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241024933617/en/2282297/4/Chris_Gibson.jpg" alt="Chris Gibson, Ph.D., Co-Founder &amp; CEO, Recursion. (Photo credit: Recursion)" /><p style="font-size:85%;">Chris Gibson, Ph.D., Co-Founder &amp; CEO, Recursion. (Photo credit: Recursion)</p></div><p> Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven http://www.streetinsider.com/Press+Releases/Cellino+Appoints+Chris+Gibson+to+Board+of+Directors/23873795.html Thu, 24 Oct 2024 08:00:00 -0400 A.40151759 EXAI O.00050368 O.50752363 RXDX http://www.streetinsider.com/Press+Releases/Cellino+Appoints+Chris+Gibson+to+Board+of+Directors/23873795.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cellinobio.com%2F&amp;esheet=54140879&amp;newsitemid=20241024933617&amp;lan=en-US&amp;anchor=Cellino+Biotech%2C+Inc.&amp;index=1&amp;md5=5a3613ab5acb4d8797c2f6fe3b89f9d1" shape="rect">Cellino Biotech, Inc.</a>, a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company’s Board of Directors. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241024933617/en/" rel="nofollow">https://www.businesswire.com/news/home/20241024933617/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241024933617/en/2282297/4/Chris_Gibson.jpg" alt="Chris Gibson, Ph.D., Co-Founder &amp; CEO, Recursion. (Photo credit: Recursion)" /><p style="font-size:85%;">Chris Gibson, Ph.D., Co-Founder &amp; CEO, Recursion. (Photo credit: Recursion)</p></div><p> Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven http://www.streetinsider.com/Press+Releases/Cellino+Appoints+Chris+Gibson+to+Board+of+Directors/23873795.html Thu, 24 Oct 2024 08:00:00 -0400 A.40151759 EXAI O.00050368 O.50752363 RXDX http://www.streetinsider.com/Press+Releases/Cellino+Appoints+Chris+Gibson+to+Board+of+Directors/23873795.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cellinobio.com%2F&amp;esheet=54140879&amp;newsitemid=20241024933617&amp;lan=en-US&amp;anchor=Cellino+Biotech%2C+Inc.&amp;index=1&amp;md5=5a3613ab5acb4d8797c2f6fe3b89f9d1" shape="rect">Cellino Biotech, Inc.</a>, a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company’s Board of Directors. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241024933617/en/" rel="nofollow">https://www.businesswire.com/news/home/20241024933617/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241024933617/en/2282297/4/Chris_Gibson.jpg" alt="Chris Gibson, Ph.D., Co-Founder &amp; CEO, Recursion. (Photo credit: Recursion)" /><p style="font-size:85%;">Chris Gibson, Ph.D., Co-Founder &amp; CEO, Recursion. (Photo credit: Recursion)</p></div><p> Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven http://www.streetinsider.com/Press+Releases/Cellino+Appoints+Chris+Gibson+to+Board+of+Directors/23873795.html Thu, 24 Oct 2024 08:00:00 -0400 A.40151759 EXAI O.00050368 O.50752363 RXDX http://www.streetinsider.com/Press+Releases/Cellino+Appoints+Chris+Gibson+to+Board+of+Directors/23873795.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cellinobio.com%2F&amp;esheet=54140879&amp;newsitemid=20241024933617&amp;lan=en-US&amp;anchor=Cellino+Biotech%2C+Inc.&amp;index=1&amp;md5=5a3613ab5acb4d8797c2f6fe3b89f9d1" shape="rect">Cellino Biotech, Inc.</a>, a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company’s Board of Directors. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241024933617/en/" rel="nofollow">https://www.businesswire.com/news/home/20241024933617/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241024933617/en/2282297/4/Chris_Gibson.jpg" alt="Chris Gibson, Ph.D., Co-Founder &amp; CEO, Recursion. (Photo credit: Recursion)" /><p style="font-size:85%;">Chris Gibson, Ph.D., Co-Founder &amp; CEO, Recursion. (Photo credit: Recursion)</p></div><p> Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven http://www.streetinsider.com/Press+Releases/Cellino+Appoints+Chris+Gibson+to+Board+of+Directors/23873795.html Thu, 24 Oct 2024 08:00:00 -0400 A.40151759 EXAI O.00050368 O.50752363 RXDX http://www.streetinsider.com/Business+Wire/Cellino+Appoints+Chris+Gibson+to+Board+of+Directors/23873795.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cellinobio.com%2F&amp;esheet=54140879&amp;newsitemid=20241024933617&amp;lan=en-US&amp;anchor=Cellino+Biotech%2C+Inc.&amp;index=1&amp;md5=5a3613ab5acb4d8797c2f6fe3b89f9d1" shape="rect">Cellino Biotech, Inc.</a>, a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company’s Board of Directors. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241024933617/en/" rel="nofollow">https://www.businesswire.com/news/home/20241024933617/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241024933617/en/2282297/4/Chris_Gibson.jpg" alt="Chris Gibson, Ph.D., Co-Founder &amp; CEO, Recursion. (Photo credit: Recursion)" /><p style="font-size:85%;">Chris Gibson, Ph.D., Co-Founder &amp; CEO, Recursion. (Photo credit: Recursion)</p></div><p> Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven http://www.streetinsider.com/Business+Wire/Cellino+Appoints+Chris+Gibson+to+Board+of+Directors/23873795.html Thu, 24 Oct 2024 08:00:00 -0400 A.40151759 EXAI O.00050368 O.50752363 RXDX http://www.streetinsider.com/Business+Wire/Cellino+Appoints+Chris+Gibson+to+Board+of+Directors/23873795.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cellinobio.com%2F&amp;esheet=54140879&amp;newsitemid=20241024933617&amp;lan=en-US&amp;anchor=Cellino+Biotech%2C+Inc.&amp;index=1&amp;md5=5a3613ab5acb4d8797c2f6fe3b89f9d1" shape="rect">Cellino Biotech, Inc.</a>, a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company’s Board of Directors. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241024933617/en/" rel="nofollow">https://www.businesswire.com/news/home/20241024933617/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241024933617/en/2282297/4/Chris_Gibson.jpg" alt="Chris Gibson, Ph.D., Co-Founder &amp; CEO, Recursion. (Photo credit: Recursion)" /><p style="font-size:85%;">Chris Gibson, Ph.D., Co-Founder &amp; CEO, Recursion. (Photo credit: Recursion)</p></div><p> Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven http://www.streetinsider.com/Business+Wire/Cellino+Appoints+Chris+Gibson+to+Board+of+Directors/23873795.html Thu, 24 Oct 2024 08:00:00 -0400 A.40151759 EXAI O.00050368 O.50752363 RXDX http://www.streetinsider.com/Business+Wire/Cellino+Appoints+Chris+Gibson+to+Board+of+Directors/23873795.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cellinobio.com%2F&amp;esheet=54140879&amp;newsitemid=20241024933617&amp;lan=en-US&amp;anchor=Cellino+Biotech%2C+Inc.&amp;index=1&amp;md5=5a3613ab5acb4d8797c2f6fe3b89f9d1" shape="rect">Cellino Biotech, Inc.</a>, a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company’s Board of Directors. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241024933617/en/" rel="nofollow">https://www.businesswire.com/news/home/20241024933617/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241024933617/en/2282297/4/Chris_Gibson.jpg" alt="Chris Gibson, Ph.D., Co-Founder &amp; CEO, Recursion. (Photo credit: Recursion)" /><p style="font-size:85%;">Chris Gibson, Ph.D., Co-Founder &amp; CEO, Recursion. (Photo credit: Recursion)</p></div><p> Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven http://www.streetinsider.com/Business+Wire/Cellino+Appoints+Chris+Gibson+to+Board+of+Directors/23873795.html Thu, 24 Oct 2024 08:00:00 -0400 A.40151759 EXAI O.00050368 O.50752363 RXDX http://www.streetinsider.com/Business+Wire/Cellino+Appoints+Chris+Gibson+to+Board+of+Directors/23873795.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cellinobio.com%2F&amp;esheet=54140879&amp;newsitemid=20241024933617&amp;lan=en-US&amp;anchor=Cellino+Biotech%2C+Inc.&amp;index=1&amp;md5=5a3613ab5acb4d8797c2f6fe3b89f9d1" shape="rect">Cellino Biotech, Inc.</a>, a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company’s Board of Directors. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241024933617/en/" rel="nofollow">https://www.businesswire.com/news/home/20241024933617/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241024933617/en/2282297/4/Chris_Gibson.jpg" alt="Chris Gibson, Ph.D., Co-Founder &amp; CEO, Recursion. (Photo credit: Recursion)" /><p style="font-size:85%;">Chris Gibson, Ph.D., Co-Founder &amp; CEO, Recursion. (Photo credit: Recursion)</p></div><p> Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven http://www.streetinsider.com/Business+Wire/Cellino+Appoints+Chris+Gibson+to+Board+of+Directors/23873795.html Thu, 24 Oct 2024 08:00:00 -0400 A.40151759 EXAI O.00050368 O.50752363 RXDX http://www.streetinsider.com/Business+Wire/Cellino+Appoints+Chris+Gibson+to+Board+of+Directors/23873795.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cellinobio.com%2F&amp;esheet=54140879&amp;newsitemid=20241024933617&amp;lan=en-US&amp;anchor=Cellino+Biotech%2C+Inc.&amp;index=1&amp;md5=5a3613ab5acb4d8797c2f6fe3b89f9d1" shape="rect">Cellino Biotech, Inc.</a>, a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company’s Board of Directors. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241024933617/en/" rel="nofollow">https://www.businesswire.com/news/home/20241024933617/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241024933617/en/2282297/4/Chris_Gibson.jpg" alt="Chris Gibson, Ph.D., Co-Founder &amp; CEO, Recursion. (Photo credit: Recursion)" /><p style="font-size:85%;">Chris Gibson, Ph.D., Co-Founder &amp; CEO, Recursion. (Photo credit: Recursion)</p></div><p> Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven http://www.streetinsider.com/Business+Wire/Cellino+Appoints+Chris+Gibson+to+Board+of+Directors/23873795.html Thu, 24 Oct 2024 08:00:00 -0400 A.40151759 EXAI O.00050368 O.50752363 RXDX http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++Prometheus+Biosciences%2C++++++++++++++/21847094.html si-local-file:///var/storage/secattach/20230627/21847094.html http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++Prometheus+Biosciences%2C++++++++++++++/21847094.html Tue, 27 Jun 2023 15:07:00 -0400 O.45905631 RXDX http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++Prometheus+Biosciences%2C++++++++++++++/21847094.html si-local-file:///var/storage/secattach/20230627/21847094.html http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++Prometheus+Biosciences%2C++++++++++++++/21847094.html Tue, 27 Jun 2023 15:07:00 -0400 O.45905631 RXDX http://www.streetinsider.com/Corporate+News/Merck+%28MRK%29+Completes+Acquisition+of+Prometheus+Biosciences+%28RXDX%29/21810161.html <p>Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. (“Prometheus”) (NASDAQ: RXDX) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or traded on the Nasdaq Global Market.</p><p> </p><p>“The Prometheus acquisition accelerates our growing presence in immunology, augments our diverse pipeline and increases our ability to deliver patient value. This transaction is another example of Merck acting strategically and decisively when science and value align,” said Robert M. Davis, chairman and chief executive officer, Merck. “Prometheus http://www.streetinsider.com/Corporate+News/Merck+%28MRK%29+Completes+Acquisition+of+Prometheus+Biosciences+%28RXDX%29/21810161.html Fri, 16 Jun 2023 16:04:30 -0400 MRK RXDX http://www.streetinsider.com/Corporate+News/Merck+%28MRK%29+Completes+Acquisition+of+Prometheus+Biosciences+%28RXDX%29/21810161.html <p>Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. (“Prometheus”) (NASDAQ: RXDX) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or traded on the Nasdaq Global Market.</p><p> </p><p>“The Prometheus acquisition accelerates our growing presence in immunology, augments our diverse pipeline and increases our ability to deliver patient value. This transaction is another example of Merck acting strategically and decisively when science and value align,” said Robert M. Davis, chairman and chief executive officer, Merck. “Prometheus http://www.streetinsider.com/Corporate+News/Merck+%28MRK%29+Completes+Acquisition+of+Prometheus+Biosciences+%28RXDX%29/21810161.html Fri, 16 Jun 2023 16:04:30 -0400 MRK RXDX http://www.streetinsider.com/Mergers+and+Acquisitions/Merck+%28MRK%29+Completes+Acquisition+of+Prometheus+Biosciences+%28RXDX%29/21810161.html <p>Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. (“Prometheus”) (NASDAQ: RXDX) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or traded on the Nasdaq Global Market.</p><p> </p><p>“The Prometheus acquisition accelerates our growing presence in immunology, augments our diverse pipeline and increases our ability to deliver patient value. This transaction is another example of Merck acting strategically and decisively when science and value align,” said Robert M. Davis, chairman and chief executive officer, Merck. “Prometheus http://www.streetinsider.com/Mergers+and+Acquisitions/Merck+%28MRK%29+Completes+Acquisition+of+Prometheus+Biosciences+%28RXDX%29/21810161.html Fri, 16 Jun 2023 16:04:30 -0400 MRK RXDX http://www.streetinsider.com/Mergers+and+Acquisitions/Merck+%28MRK%29+Completes+Acquisition+of+Prometheus+Biosciences+%28RXDX%29/21810161.html <p>Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. (“Prometheus”) (NASDAQ: RXDX) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or traded on the Nasdaq Global Market.</p><p> </p><p>“The Prometheus acquisition accelerates our growing presence in immunology, augments our diverse pipeline and increases our ability to deliver patient value. This transaction is another example of Merck acting strategically and decisively when science and value align,” said Robert M. Davis, chairman and chief executive officer, Merck. “Prometheus http://www.streetinsider.com/Mergers+and+Acquisitions/Merck+%28MRK%29+Completes+Acquisition+of+Prometheus+Biosciences+%28RXDX%29/21810161.html Fri, 16 Jun 2023 16:04:30 -0400 MRK RXDX http://www.streetinsider.com/Press+Releases/Merck+Completes+Acquisition+of+Prometheus+Biosciences%2C+Inc./21810153.html <p class="bwalignc"> <b>Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions</b> </p> <p> RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. (“Prometheus”) (NASDAQ: RXDX) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or traded on the Nasdaq Global Market. </p><p> “The Prometheus acquisition accelerates our growing presence in immunology, augments our diverse pipeline and increases our ability to deliver patient value. This http://www.streetinsider.com/Press+Releases/Merck+Completes+Acquisition+of+Prometheus+Biosciences%2C+Inc./21810153.html Fri, 16 Jun 2023 16:04:00 -0400 MRK O.00037438 O.45905631 RXDX http://www.streetinsider.com/Press+Releases/Merck+Completes+Acquisition+of+Prometheus+Biosciences%2C+Inc./21810153.html <p class="bwalignc"> <b>Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions</b> </p> <p> RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. (“Prometheus”) (NASDAQ: RXDX) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or traded on the Nasdaq Global Market. </p><p> “The Prometheus acquisition accelerates our growing presence in immunology, augments our diverse pipeline and increases our ability to deliver patient value. This http://www.streetinsider.com/Press+Releases/Merck+Completes+Acquisition+of+Prometheus+Biosciences%2C+Inc./21810153.html Fri, 16 Jun 2023 16:04:00 -0400 MRK O.00037438 O.45905631 RXDX http://www.streetinsider.com/Press+Releases/Merck+Completes+Acquisition+of+Prometheus+Biosciences%2C+Inc./21810153.html <p class="bwalignc"> <b>Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions</b> </p> <p> RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. (“Prometheus”) (NASDAQ: RXDX) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or traded on the Nasdaq Global Market. </p><p> “The Prometheus acquisition accelerates our growing presence in immunology, augments our diverse pipeline and increases our ability to deliver patient value. This http://www.streetinsider.com/Press+Releases/Merck+Completes+Acquisition+of+Prometheus+Biosciences%2C+Inc./21810153.html Fri, 16 Jun 2023 16:04:00 -0400 MRK O.00037438 O.45905631 RXDX http://www.streetinsider.com/Press+Releases/Merck+Completes+Acquisition+of+Prometheus+Biosciences%2C+Inc./21810153.html <p class="bwalignc"> <b>Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions</b> </p> <p> RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. (“Prometheus”) (NASDAQ: RXDX) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or traded on the Nasdaq Global Market. </p><p> “The Prometheus acquisition accelerates our growing presence in immunology, augments our diverse pipeline and increases our ability to deliver patient value. This http://www.streetinsider.com/Press+Releases/Merck+Completes+Acquisition+of+Prometheus+Biosciences%2C+Inc./21810153.html Fri, 16 Jun 2023 16:04:00 -0400 MRK O.00037438 O.45905631 RXDX http://www.streetinsider.com/Business+Wire/Merck+Completes+Acquisition+of+Prometheus+Biosciences%2C+Inc./21810153.html <p class="bwalignc"> <b>Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions</b> </p> <p> RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. (“Prometheus”) (NASDAQ: RXDX) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or traded on the Nasdaq Global Market. </p><p> “The Prometheus acquisition accelerates our growing presence in immunology, augments our diverse pipeline and increases our ability to deliver patient value. This http://www.streetinsider.com/Business+Wire/Merck+Completes+Acquisition+of+Prometheus+Biosciences%2C+Inc./21810153.html Fri, 16 Jun 2023 16:04:00 -0400 MRK O.00037438 O.45905631 RXDX http://www.streetinsider.com/Business+Wire/Merck+Completes+Acquisition+of+Prometheus+Biosciences%2C+Inc./21810153.html <p class="bwalignc"> <b>Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions</b> </p> <p> RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. (“Prometheus”) (NASDAQ: RXDX) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or traded on the Nasdaq Global Market. </p><p> “The Prometheus acquisition accelerates our growing presence in immunology, augments our diverse pipeline and increases our ability to deliver patient value. This http://www.streetinsider.com/Business+Wire/Merck+Completes+Acquisition+of+Prometheus+Biosciences%2C+Inc./21810153.html Fri, 16 Jun 2023 16:04:00 -0400 MRK O.00037438 O.45905631 RXDX http://www.streetinsider.com/Business+Wire/Merck+Completes+Acquisition+of+Prometheus+Biosciences%2C+Inc./21810153.html <p class="bwalignc"> <b>Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions</b> </p> <p> RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. (“Prometheus”) (NASDAQ: RXDX) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or traded on the Nasdaq Global Market. </p><p> “The Prometheus acquisition accelerates our growing presence in immunology, augments our diverse pipeline and increases our ability to deliver patient value. This http://www.streetinsider.com/Business+Wire/Merck+Completes+Acquisition+of+Prometheus+Biosciences%2C+Inc./21810153.html Fri, 16 Jun 2023 16:04:00 -0400 MRK O.00037438 O.45905631 RXDX http://www.streetinsider.com/Business+Wire/Merck+Completes+Acquisition+of+Prometheus+Biosciences%2C+Inc./21810153.html <p class="bwalignc"> <b>Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions</b> </p> <p> RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. (“Prometheus”) (NASDAQ: RXDX) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or traded on the Nasdaq Global Market. </p><p> “The Prometheus acquisition accelerates our growing presence in immunology, augments our diverse pipeline and increases our ability to deliver patient value. This http://www.streetinsider.com/Business+Wire/Merck+Completes+Acquisition+of+Prometheus+Biosciences%2C+Inc./21810153.html Fri, 16 Jun 2023 16:04:00 -0400 MRK O.00037438 O.45905631 RXDX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Prometheus+Biosciences%2C+++For%3A+Jun+16++Filed+by%3A+Hassan+Fred/21810085.html si-local-file:///var/storage/secattach/20230616/21810085.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Prometheus+Biosciences%2C+++For%3A+Jun+16++Filed+by%3A+Hassan+Fred/21810085.html Fri, 16 Jun 2023 16:01:00 -0400 O.45905631 RXDX